| | |
| Clinical data | |
|---|---|
| Other names | KW-6356 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C20H19N3O4S |
| Molar mass | 397.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sipagladenant (KW-6356) is a non-xanthine selective antagonist/inverse agonist of the adenosine A2A receptor that was previously under development by Kyowa Kirin as a monotherapy and adjunctive to levodopa therapy in Parkinsonism. [1]
KW-6356 is a selective A2A adenosine antagonist/inverse agonist displaying insurmountable antagonism of this adenosine subtype. Compared to the first generation A2A adenosine inverse agonist Istradefylline, KW-6356 possesses a 100-fold greater affinity for the A2A adenosine receptor and dissociates more slowly from the receptor. [2]
The metabolism of KW-6356 generates M6, an active metabolite with similar potency as a A2A antagonist/inverse agonist. [2]
The half-life of KW-6356 is 22.9 hours. The half-life of M6 is 4.34 hours. [2]
Kyowa Kirin halted development of KW-6356 in 2022 based on regulatory and developmental challenges surrounding the drug. [3]